Aims: The eligibility of complex congenital heart disease (C-CHD) patients for subcutaneous implantable cardioverter-defibrillator (S-ICD) has yet to be determined. The aim of this study was to determine in C-CHD patients: (i) the S-ICD eligibility, (ii) the most effective sensing vector, (iii) the impact of posture change on screening eligibility, and (iv) the impact of using two vs. six postures for screening. Adults with structurally normal hearts were used as controls.
Methods And Results: The Boston Scientific ECG screening tool was used to determine eligibility for S-ICD in two and six different postures in 30 patients with C-CHD and 10 controls. Statistical significance was determined using Fisher's exact test. In total, 1440 bipolar vectors were collected. The mean age was 36.3 years, 57% subjects were men. Over all 86.7% of C-CHD patients and 100% controls (P > 0.05) met S-ICD eligibility. In controls, the primary vector (PV) was the most effective, and the alternate vector (AV) was least effective. In C-CHD patients, the AV was comparable to the PV. Posture change did not significantly affect S-ICD eligibility in C-CHD patients and controls (P > 0.05). Screening with six postures vs. two did not significantly affect S-ICD eligibility of C-CHD patients (83% vs. 87%, P > 0.05) or controls (90% vs. 100% P = >0.05).
Conclusion: No significant differences were observed between S-ICD eligibility in C-CHD patients and controls. The AV and PV are most suitable in C-CHD patients. No significant impact of postural change was observed for S-ICD eligibility between the two groups. No significant difference was observed in S-ICD eligibility when screening using two or six postures in both groups.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1093/europace/euu375 | DOI Listing |
Zhonghua Xin Xue Guan Bing Za Zhi
May 2022
Department of Cardiothoracic Surgery, National Children's Medical Center, Shanghai Children's Medical Center Affiliated to Shanghai Jiaotong University School of Medicine, Shanghai 200127, China.
To investigate the postoperative cardiopulmonary fitness of children with congenital heart diseases (CHD). This is a retrospective study. A total of 136 children after cardiac correction undergoing cardiopulmonary exercise test (CPET) in Shanghai Children's Medical Center from March 1 to June 30, 2021 were selected.
View Article and Find Full Text PDFBiomaterials
February 2020
Department of Cardiovascular Surgery, The Second Affiliated Hospital of Harbin Medical University, Harbin, Heilongjiang Province, China; The Key Laboratory of Myocardial Ischemia, Harbin Medical University, Ministry of Education, Heilongjiang Province, China. Electronic address:
Engineered heart tissues (EHTs) are regarded as being the most promising alternative to synthetic materials, and autologous mesenchymal stem cells (MSCs) are widely used as seeding cells. However, few studies have evaluated the feasibility of using MSCs from patients with cyanotic congenital heart disease (C-CHD) as seeding cells for EHTs, in comparison with cells from patients of acyanotic congenital heart disease (A-CHD). In the present study, we cultured MSCs from A-CHD and C-CHD patients in normoxia or hypoxia conditions, and compared their pro-angiogenic, anti-apoptotic and inflammation-modulatory potentials.
View Article and Find Full Text PDFMuscle Nerve
March 2017
Office of the Clinical Director, Human Genome Research Institute, NIH, Bethesda, Maryland, USA.
Introduction: Chediak-Higashi disease (CHD) is a rare autosomal recessive disorder with hematologic, infectious, pigmentary, and neurologic manifestations. Classic CHD (C-CHD) presents in early childhood with severe infectious or hematologic complications unless treated with bone marrow transplantation. Atypical CHD (A-CHD) has less severe hematologic and infectious manifestations.
View Article and Find Full Text PDFInfect Dis (Lond)
October 2016
a CHU Hôtel-Dieu, Infectious Diseases Department , Nantes University Hospital, Nantes , France ;
Background: Tenofovir DF/FTC/rilpivirine (TDF/FTC/RPV) is a single tablet regimen considered as safe and efficacious in HIV population as long as food requirements, concomitant PPI administration, and compromised antiviral activity have been carefully reviewed. We evaluated TDF/FTC/RPV in a real-life setting with focus on clinical and virological outcomes.
Methods: OCEAN II is a prospective, two-centre observational study.
Europace
July 2015
Clinical Cardiology Research Fellow, Wessex Cardiac Unit, Southampton University Hospitals NHS Trust, Tremona Road, Southampton SO16 6YD, UK Faculty of Medicine, University of Southampton, Southampton, UK.
Aims: The eligibility of complex congenital heart disease (C-CHD) patients for subcutaneous implantable cardioverter-defibrillator (S-ICD) has yet to be determined. The aim of this study was to determine in C-CHD patients: (i) the S-ICD eligibility, (ii) the most effective sensing vector, (iii) the impact of posture change on screening eligibility, and (iv) the impact of using two vs. six postures for screening.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!